ABSCIENCES (EPA:AB) | WebDisclosure

Basculer en Français

8205	Companies
109437	Keywords
51603	Articles
60273	Press releases

Home
Companies
ABSCIENCES

PRESS RELEASE

published on 07/08/2024 at 07:56, 3 months 27 days ago

AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19
AB Science annonce des résultats positifs de son étude de phase 2 évaluant le masitinib dans la COVID-19. Les analyses montrent un potentiel traitement prometteur pour les patients hospitalisés

COVID-19 Traitement Étude De Phase 2 AB Science Masitinib
PRESS RELEASE

published on 07/08/2024 at 07:56, 3 months 27 days ago

AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19
AB Science reports positive results of its phase 2 study evaluating masitinib in COVID-19, showing improved clinical status in hospitalized patients. Study indicates potential for masitinib as a COVID-19 treatment

COVID-19 Treatment Phase 2 Study AB Science Masitinib
BRIEF

published on 06/28/2024 at 12:36, 4 months 6 days ago

AB Science fait le point sur la demande d'autorisation du masitinib dans la SLA

Autorisation De Mise Sur Le Marché AB Science Masitinib EMA SLA
BRIEF

published on 06/28/2024 at 12:36, 4 months 6 days ago

AB Science provides an update on the application for authorization of masitinib in ALS

ALS AB Science Masitinib EMA Marketing Authorization
PRESS RELEASE

published on 06/28/2024 at 12:31, 4 months 6 days ago

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
AB Science annonce un avis négatif sur la demande de mise sur le marché du masitinib dans la SLA et prévoit un réexamen du dossier. Détails sur les raisons et les prochaines étapes

AB Science Masitinib Sclérose Latérale Amyotrophique Autorisation Conditionnelle Réexamen Dossier
PRESS RELEASE

published on 06/28/2024 at 12:31, 4 months 6 days ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science receives negative opinion from CHMP on masitinib's conditional marketing authorization for ALS treatment but plans re-examination due to urgent patient need and safety considerations

AB Science Masitinib CHMP ALS Treatment Conditional Marketing Authorization
BRIEF

published on 06/27/2024 at 10:20, 4 months 7 days ago

AB Science - Results of the Combined General Meeting of June 26, 2024

Shareholders Share Capital Resolutions General Assembly AB Science
BRIEF

published on 06/27/2024 at 10:20, 4 months 7 days ago

AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024

Actionnaires Capital Social Assemblée Générale Resolutions AB Science
PRESS RELEASE

published on 06/27/2024 at 10:15, 4 months 7 days ago

AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024
Assemblée Générale Mixte de AB Science du 26 juin 2024 : toutes les résolutions ordinaires et extraordinaires adoptées sauf une. Actionnariat présent : 21.948.183 actions ordinaires et 38.495.615 droits de vote

Actionnaires Droits De Vote Assemblée Générale Resolutions AB Science
BRIEF

published on 05/17/2024 at 18:03, 5 months 18 days ago

Correction of the Consolidated Accounts of AB Science for 2023

Financial Results Research And Development Consolidated Accounts AB Science Accounting Correction

Accesswire

Published on 11/05/2024 at 03:30, 1 hour 37 minutes ago

CORRECTION: Savencia Cheese USA Announces Voluntary Recall of Select Soft Ripened Cheeses
Published on 11/05/2024 at 00:00, 5 hours 7 minutes ago

Axcap Ventures Announces Upsizing of Private Placement
Published on 11/04/2024 at 23:00, 6 hours 7 minutes ago

Jericho Energy Ventures Announces Plan to Separate Hydrogen Platform from Traditional Energy Assets to Maximize Shareholder Value
Published on 11/04/2024 at 23:00, 6 hours 7 minutes ago

APEX/IFSA Global EXPO Showcases the Future of Aviation With Nearly 3,000 Industry ‎Professionals in Attendance
Published on 11/04/2024 at 22:45, 6 hours 22 minutes ago

Alphinat Announces a Profit of $160,597 for Fiscal Year Ended August 31, 2023

View all ACCESSWIRE

EQS Group

Published on 11/04/2024 at 22:20, 6 hours 47 minutes ago

Adler Group S.A. announces the sale of its 62.78% stake in Brack Capital Properties N.V. to LEG Immobilien SE
Published on 11/04/2024 at 21:15, 7 hours 52 minutes ago

EQS-Adhoc: LEG Immobilien SE: Acquisition of Brack Capital Properties N.V. through the conclusion of a share purchase agreement and a tender commitment in the event of a public offer
Published on 11/04/2024 at 19:00, 10 hours 7 minutes ago

EQS-Adhoc: Salzgitter Aktiengesellschaft: Potential voluntary public takeover bid to the shareholders of Salzgitter AG
Published on 11/04/2024 at 19:00, 10 hours 7 minutes ago

PATRIMOINE ET COMMERCE: Déclaration des transactions sur actions propres (Hors contrat de liquidité) réalisées du 28 OCTOBRE 2024 au 01 NOVEMBRE 2024
Published on 11/04/2024 at 19:00, 10 hours 7 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF

Les Echos

Published on 11/04/2024 at 18:13, 10 hours 54 minutes ago

Thales : lancement de l’opération 2024 d’actionnariat salarié
Published on 11/04/2024 at 18:13, 10 hours 54 minutes ago

Thales: Launch of the 2024 Employee Share Ownership Plan
Published on 11/04/2024 at 18:11, 10 hours 55 minutes ago

Monthly disclosure of the total number of shares and voting rights - 31/10/2024
Published on 11/04/2024 at 18:11, 10 hours 55 minutes ago

Déclaration mensuelle des actions et droits de vote – 31/10/2024
Published on 11/04/2024 at 17:45, 11 hours 22 minutes ago

Disclosure of trading in own shares from October 29th, 2024, to November 1st, 2024. Detailed information per transaction.

View all LES ECHOS COMFI WIRE